https://www.selleckchem.com/pr....oducts/jak-inhibitor
From a metabolic perspective, significant improvements were observed in the reduction in body weight (SMD -0.68, 95% CI -1.16 to -0.19, 0.01), fasting plasma glucose (FPG) (SMD -0.59, 95% CI -0.99 to -0.19, P0.01), and insulin resistance as assessed with the HOMA-IR (SMD -0.39, 95% CI -0.76 to -0.03, P=0.03). In addition, a significant improvement was noted in dehydroepiandrosterone sulphate (DHEAS) levels (SMD -0.55, 95% CI -0.94 to -0.16, P0.01). SGLT-2i use is associated with salutary outcomes of metabolic and ant
Like
Comment
Share
